Asset Details
Do you wish to reserve the book?
Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT
Do you wish to request the book?
Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT
2017
Overview
Gemtuzumab ozogamicin (GO) may increase the risk of sinusoidal obstruction syndrome (SOS) when used prior to allogeneic stem cell transplantation (HSCT). We assessed SOS incidence and outcomes after HSCT of 146 adults, with a median age of 50 years, previously receiving GO. SOS prophylaxis was used in 69 patients (heparin
n
=57, ursodeoxycholic acid
n
=8, defibrotide
n
=4). Cumulative incidence (CI) of SOS was 8% (
n
=11), with death in 3 patients. Median interval between last GO dose and HSCT was 130 days. Overall survival (OS) and SOS incidence did not differ for patients receiving GO ⩽3.5 months before HSCT and the others. CI of acute and chronic GVHD was 31% and 25%, respectively. Probability of OS and leukemia-free survival (LFS) at 5 years was 40% and 37%, respectively. Relapse incidence and non-relapse mortality were 42% and 21%, respectively. In multivariate analysis, active disease at HSCT was associated with relapse and worse LFS and OS (
P
<0.03). Liver abnormalities before HSCT correlated with worse OS (
P
<0.03). Use of low-dose GO prior to HSCT is associated with an acceptable SOS incidence. Prospective studies investigating the role and the utility of SOS prophylaxis are warranted.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ 692/700
/ Adult
/ Aged
/ Aminoglycosides - therapeutic use
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Antibodies, Monoclonal, Humanized - toxicity
/ Complications and side effects
/ Female
/ Hematopoietic Stem Cell Transplantation - adverse effects
/ Heparin
/ Hepatic Veno-Occlusive Disease - etiology
/ Hepatic Veno-Occlusive Disease - mortality
/ Hepatic Veno-Occlusive Disease - prevention & control
/ Humans
/ Leukemia
/ Male
/ Medicine
/ Patients
/ Survival
